Arvinas

Youtube Subscribe

Open: 28.34 Close: 27.01 Change: -1.33

Stop reading the whole internet to decide if you want to invest in Arvinas Company Inc.

This document will help you to evaluate Arvinas without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: Arvinas, price, protein, company, share, focus, pipeline, and the …

Concept Map

Semantic Network

Stock Summary

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that.

Today's Summary

Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $90.00 price objective on shares. The rise in share price is attributable to positive investor expectations.

Today's News

Arvinas, Inc. (ARVN) Surges 7.6%: Is This an indication of further gains? - april 14, 2023 - zacks.com. The rise in share price is attributable to positive investor expectations for Arvinis pipeline that focuses on developing therapies that degrade disease-causing proteins. Arvinas is a clinical-stage biotechnology company leading the way in targeted protein degradation therapeutics. The company is the first company to focus solely on protein degradation and its platform technology is the most advanced in the field. The pipeline encompasses a range of validated and undruggable targets in oncology, immuno-oncology. Arvinas is the first company to focus solely on protein degradation and its platform technology is the most advanced in the field. The rise in share price is attributable to positive investor expectations for the companys pipeline that focuses on developing therapies that degrade disease-causing proteins. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $90.00 price objective on shares of Arvinas. Cantor Fitzgerald has a “buy’s’ buy-in’t target price on shares. Shares of NASDAQ:ARVN opened at $26. Arvinas Inc stock price today is $27.26.26. The 52-week high is $67.10 as of April 19, 2023. The P/E ratio is -5.13.13. EBITDA is a widely used measure of corporate profitability.

Stock Profile

"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut."

Keywords

Are looking for the most relevant information about Arvinas? Investor spend a lot of time searching for information to make investment decisions in Arvinas. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Arvinas are: Arvinas, price, protein, company, share, focus, pipeline, and the most common words in the summary are: clinical, trial, leader, salary, arvinas, therapeutic, job, . One of the sentences in the summary was: The rise in share price is attributable to positive investor expectations.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #clinical #trial #leader #salary #arvinas #therapeutic #job.

Read more →

Youtube Subscribe

---